Search research articles
Contact Us
Filters
Showing results (21-30 of 43) with videos related to
Page
of 5
Sort By:
Hemasphere
|
June 24, 2022
European LeukemiaNet Response Predicts Disease Progression but Not Thrombosis in Polycythemia Vera
Douglas Tremblay, Andrew Srisuwananukorn, Lukas Ronner, et al.
The Journal of Clinical Investigation
|
October 19, 2004
Human mitochondrial peptide deformylase, a new anticancer target of actinonin-based antibiotics
Mona D Lee, Yuhong She, Michael J Soskis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 7, 2005
Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies
Owen A O'Connor, Mark L Heaney, Lawrence Schwartz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 23, 2010
Sequential cytarabine and alpha-particle immunotherapy with bismuth-213-lintuzumab (HuM195) for acute myeloid leukemia
Todd L Rosenblat, Michael R McDevitt, Deborah A Mulford, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
July 26, 2005
Myeloid growth factors clinical practice guidelines in oncology
Jeffrey Crawford, Betsy Althaus, James Armitage, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
September 9, 2011
Myeloid growth factors
Jeffrey Crawford, Jeffrey Allen, James Armitage, et al.
Blood
|
August 12, 2006
Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics
Daniel J DeAngelo, Richard M Stone, Mark L Heaney, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 2, 2015
Polycythemia Vera: An Appraisal of the Biology and Management 10 Years After the Discovery of JAK2 V617F
Brady L Stein, Stephen T Oh, Dmitriy Berenzon, et al.
Pediatric Blood & Cancer
|
November 3, 2016
A phase IIa study of afuresertib, an oral pan-AKT inhibitor, in patients with Langerhans cell histiocytosis
Robert J Arceci, Carl E Allen, Ira J Dunkel, et al.
Blood
|
May 23, 2014
Consensus guidelines for the diagnosis and clinical management of Erdheim-Chester disease
Eli L Diamond, Lorenzo Dagna, David M Hyman, et al.
Page
of 5
Search research articles
Search
Showing results (21-30 of 43) with videos related to
Sort By:
Page
of 5
Hemasphere
|
June 24, 2022
European LeukemiaNet Response Predicts Disease Progression but Not Thrombosis in Polycythemia Vera
Douglas Tremblay, Andrew Srisuwananukorn, Lukas Ronner, et al.
The Journal of Clinical Investigation
|
October 19, 2004
Human mitochondrial peptide deformylase, a new anticancer target of actinonin-based antibiotics
Mona D Lee, Yuhong She, Michael J Soskis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 7, 2005
Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies
Owen A O'Connor, Mark L Heaney, Lawrence Schwartz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 23, 2010
Sequential cytarabine and alpha-particle immunotherapy with bismuth-213-lintuzumab (HuM195) for acute myeloid leukemia
Todd L Rosenblat, Michael R McDevitt, Deborah A Mulford, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
July 26, 2005
Myeloid growth factors clinical practice guidelines in oncology
Jeffrey Crawford, Betsy Althaus, James Armitage, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
September 9, 2011
Myeloid growth factors
Jeffrey Crawford, Jeffrey Allen, James Armitage, et al.
Blood
|
August 12, 2006
Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics
Daniel J DeAngelo, Richard M Stone, Mark L Heaney, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 2, 2015
Polycythemia Vera: An Appraisal of the Biology and Management 10 Years After the Discovery of JAK2 V617F
Brady L Stein, Stephen T Oh, Dmitriy Berenzon, et al.
Pediatric Blood & Cancer
|
November 3, 2016
A phase IIa study of afuresertib, an oral pan-AKT inhibitor, in patients with Langerhans cell histiocytosis
Robert J Arceci, Carl E Allen, Ira J Dunkel, et al.
Blood
|
May 23, 2014
Consensus guidelines for the diagnosis and clinical management of Erdheim-Chester disease
Eli L Diamond, Lorenzo Dagna, David M Hyman, et al.
Page
of 5